MarketPulse
X

$XAIR

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Beyond Air, Inc.

Beyond Cancer's UNO Therapy Shows Durable Survival Gains in Early-Stage Cancer Trial

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.
XAIRbreast cancercancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Beyond Air, Inc.

Beyond Air to Present Nitric Oxide Pipeline at Roth Conference

Beyond Air ($XAIR) will present at the 38th Annual Roth Conference in March, showcasing its nitric oxide therapy platform for respiratory and oncology applications.
XAIRbiopharmaceuticalmedical device
GlobeNewswire Inc.GlobeNewswire Inc.··Beyond Air, Inc.

Peer-Reviewed Study Validates High-Dose Inhaled Nitric Oxide for Respiratory Infections

Peer-reviewed study validates Beyond Air's high-dose inhaled nitric oxide for treating respiratory infections including pneumonia, COVID-19, and bronchiolitis, supporting regulatory advancement.
XAIRclinical trialshigh-dose inhaled nitric oxide